

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:
DEAV2001/0073 US NP

Applicants:
WEITHMANN, et al.

Serial No.
10/065,994

Filing Date:
December 9, 2002

Title of Invention:
**PYRIDINE-2,4-DICARBOXYLIC ACID DIAMIDES AND PYRIMIDINE-4,6-DICARBOXYLIC ACID
DIAMIDES AND THE USE THEREOF FOR SELECTIVELY INHIBITING COLLAGENASES**

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, Mail Stop RCE, at 703 872-9306, on
Date of Deposit November 16, 2004

Printed Name of Person Signing Certificate Paul Irvine

Signature 

Total Number of Pages Sent: 18

Attorney: Joseph D. Rossi

Group Art Unit: 1624

Examiner: Habte, Kahsay

TO: Mail Stop RCE
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

**RECEIVED
CENTRAL FAX CENTER
NOV 16 2004**

Please acknowledge receipt of the below-listed documents for the above Application, by return telefax to
(908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of
Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input checked="" type="checkbox"/> Amendment, 37 CFR § 1.116 | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>RCE TRANSMITTAL SHEET</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)